MAP2K7 and non-small cell lung carcinoma: In addition, more treatment options for patients with BRAF mutations can be explored, for example, BRAF inhibitors as adjuvant/neoadjuvant therapy for patients with NSCLC; BRAF inhibitor combined with MEK inhibitor and EGFR-TKI as three-target combination therapy; BRAF inhibitors combined with immunotherapy, anti-angiogenic drugs and other drug combinations.